/

PathAI

☆☆☆☆☆0.0
1 reviews
  • What it is:PathAI is a leading provider of AI-powered pathology solutions for biopharma, labs, and clinicians to improve patient outcomes through biomarker discovery, drug development, and digital pathology workflows.
  • Best for:Pharmaceutical companies, Research institutions and universities, Large pathology laboratories
  • Pricing:Starting from Custom Enterprise
  • Rating:82/100Very Good
  • Expert's conclusion:PathAI is the best solution for pharmaceutical companies and forward-thinking diagnostic laboratories willing to invest in a regulated, AI driven precision pathology solution to enhance accuracy, and accelerate drug development.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is PathAI and What Does It Do?

PathAI is a leader in the field of AI for pathology research and provides research tools and services to leading life science companies and researchers who are working on developing new approaches to precision medicine. Through the use of its platform, PathAI is able to enhance both the quality of diagnoses and the effectiveness of treatments for many diseases such as cancer, by improving the accuracy of machine learning based algorithms used for the analysis of digital pathology.

Active
📍Boston, MA
📅Founded 2016
🏢Private
TARGET SEGMENTS
Pharmaceutical CompaniesBiotech FirmsClinical LaboratoriesHealthcare ProvidersMedical Device CompaniesResearchers

What Are PathAI's Key Business Metrics?

📊
$255M
Total Funding
📊
$165M (Series C)
Most Recent Funding
📊
4
Funding Rounds
💵
$106.7M
Annual Revenue
📊
18
Patents Filed
🏢
505
Employees

How Credible and Trustworthy Is PathAI?

82/100
Good

PathAI has demonstrated its ability to establish credibility through large amounts of funding received from investors, significant levels of revenue generated, partnerships with major players within the industry, and continuous innovation. PathAI has established itself as one of the major players in AI powered pathology and is continuing to grow with each passing month with respect to its number of clinical deployments.

BREAKDOWN
Product Maturity80/100
Company Stability85/100
Security & Compliance75/100
User Reviews80/100
Transparency78/100
Support Quality80/100
TRUST SIGNALS
Partnerships with Fortune 500 companies (Roche)$255M in total funding from top-tier investors$106.7M annual revenue demonstrates commercial tractionCollaborations with leading medical institutions (Cleveland Clinic, LabCorp)18 granted patents in machine learning and biomedical imagingDeployed across pharmaceutical drug development and clinical diagnostics

What is the history of PathAI and its key milestones?

2016

Company Founded

PathAI was founded by Andrew H. Beck and Aditya Khosla with the goal of utilizing AI to decrease error rates and increase the accuracy and reproducibility in pathology.

2017

Pharmaceutical Partnerships Begin

PathAI began establishing partnerships with several pharmaceutical companies in order to provide support for their drug development initiatives through the use of AI powered pathology analysis.

2021

Series C Funding and Clinical Expansion

PathAI raised $165 million dollars in Series C funding led by D1 Capital Partners and Kaiser Permanente which enabled PathAI to expand into clinical diagnostics through the acquisition of Poplar Healthcare PLLC.

2022

Strategic Partnerships Established

PathAI has formed major industry collaborations with other companies, including a collaboration with Roche for cancer diagnostics, a collaboration with LabCorp for drug development, and a collaboration with the Cleveland Clinic for clinical applications.

2024

Scale Deployments and AI Integrations

PathAI is also the first company to utilize AI in order to deploy biospecimen solutions at scale with Discovery Life Sciences; integrate Deep Bio's DeepDx Prostate Algorithm into PathAI's AISight IMS platform; and collaborate with Clario in order to create integrated GI clinical trial solutions.

What Are the Key Features of PathAI?

✨
AI-Powered Pathology Analysis
PathAI utilizes machine learning models to analyze pathology images so that it can assist in enhancing the diagnostic accuracy and decreasing the amount of human error associated with disease diagnosis and classification.
📊
AISight IMS Platform
PathAI utilizes an integrated imaging platform for image analysis and management that assists in creating standardized digital pathology workflows for both research and clinical environments.
✨
Biomarker Detection and Quantification
Identifying and measuring biomarkers for disease, such as PD-L1, HER2, CD8 and others that are relevant to treatment choice and drug development, automatically and accurately.
💬
Translational Research Support
Identifying new insights for pharmaceutical companies in pharmacodynamics, mechanism of action, and patient stratification during drug development trials.
✨
Clinical Diagnostic Services
A full service laboratory diagnostic capability that combines AI analysis with clinical expertise for diagnosis of a patient and treatment planning.
✨
Graph Neural Network Classification
Using advanced machine learning techniques, specifically Graph Neural Networks, to improve classification accuracy of biomedical images for pathology analysis.
✨
Multi-disease Coverage
Training AI models across multiple disease areas, including; cancer (HER2, PD-L1, TME), liver disease (NASH) and gastrointestinal disease.
🔗
Integration and Interoperability
Integrates with the platforms and institutions of partners to provide a seamless flow of work and data.

What Technology Stack and Infrastructure Does PathAI Use?

Infrastructure

Cloud-based platform supporting on-site and off-site sample analysis

Technologies

Machine LearningGraph Neural NetworksArtificial Neural NetworksPythonImage Processing

Integrations

Deep Bio DeepDx algorithmsLaboratory Information SystemsClinical trial platformsBiobank systems

AI/ML Capabilities

Proprietary machine learning models including graph neural networks for biomedical image classification, with specialized algorithms for cancer biomarkers (PD-L1, HER2, CD8), liver disease analysis (NASH), and other disease domains.

Based on published research, patent filings, and company collaborations announced through press releases and industry publications

What Are the Best Use Cases for PathAI?

Pharmaceutical Companies
Enable the acceleration of drug development by identifying which patient populations would be the most responsive to treatments, improving the accuracy of biomarkers and enabling patient stratification with an increase of 40% or greater in identifying biomarker positive patients.
Clinical Laboratory Providers
Enhance the accuracy and throughput of diagnostics by automating the analysis of pathology images, reduce the workload of pathologists and provide standardized, reproducible results at scale.
Hospital and Health Systems
Improve patient outcomes in oncology and gastroenterology by enabling more accurate cancer diagnosis, selecting the best treatment option for a patient based on biomarkers of their tumor and providing fast turnaround times for diagnostic results.
Medical Device and Diagnostic Companies
Support the global development and commercialization of AI powered diagnostic tools with regulatory pathways, validation data and integration into existing diagnostic platforms.
Biobanks and Research Institutions
Clinical Trial Sponsors
Improve patient enrollment and assess outcomes in gastroenterology and other specialty trials using more accurate diagnostic algorithms and standardized image analysis. The following is a paraphrasing of the selected text within the confines of the marker (BEGIN_TEXT) and (END_TEXT).
NOT FORReal-time Pathology Decision Support
It does not allow for instant decision making during an intraoperative procedure. The PathAI is best suited for post-operative clinical diagnoses and research work flows.
NOT FORStandalone Small Pathology Practices
Small, independent laboratories that do not have an existing digital pathology system and/or low volume to warrant enterprise wide application of the platform may be limited as to what they can accomplish with PathAI.

How Much Does PathAI Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Research PlatformCustom EnterpriseAcademic research, biomarker discovery for universities and research institutionsTechVernia review
Pharma PartnershipsCustom EnterpriseClinical trials, drug development for pharmaceutical companies and CROsTechVernia review
Clinical SolutionsCustom EnterpriseDiagnostic support, QA tools for pathology laboratories and hospitalsTechVernia review
Algorithm DevelopmentCustom EnterpriseCustom AI model creation for partners developing proprietary algorithmsTechVernia review
Research PlatformCustom Enterprise
Academic research, biomarker discovery for universities and research institutions
TechVernia review
Pharma PartnershipsCustom Enterprise
Clinical trials, drug development for pharmaceutical companies and CROs
TechVernia review
Clinical SolutionsCustom Enterprise
Diagnostic support, QA tools for pathology laboratories and hospitals
TechVernia review
Algorithm DevelopmentCustom Enterprise
Custom AI model creation for partners developing proprietary algorithms
TechVernia review

How Does PathAI Compare to Competitors?

FeaturePathAIPaige AI
Core FunctionalityPharma partnerships, biomarker quantification, research & clinical trialsClinical diagnostics, cancer detection
PricingCustom EnterpriseCustom Enterprise
Free TierNoNo
Enterprise FeaturesYes (AISight platform, regulatory clearances)Yes (FDA-approved tools)
API AvailabilityYes (via AWS Marketplace)Yes
Integration CountEHR integration, real-world data partnersClinical workflow integration
Support OptionsDedicated partnershipsClinical support
Security CertificationsFDA 510(k), CE Mark, EMA qualificationFDA approvals
Core Functionality
PathAIPharma partnerships, biomarker quantification, research & clinical trials
Paige AIClinical diagnostics, cancer detection
Pricing
PathAICustom Enterprise
Paige AICustom Enterprise
Free Tier
PathAINo
Paige AINo
Enterprise Features
PathAIYes (AISight platform, regulatory clearances)
Paige AIYes (FDA-approved tools)
API Availability
PathAIYes (via AWS Marketplace)
Paige AIYes
Integration Count
PathAIEHR integration, real-world data partners
Paige AIClinical workflow integration
Support Options
PathAIDedicated partnerships
Paige AIClinical support
Security Certifications
PathAIFDA 510(k), CE Mark, EMA qualification
Paige AIFDA approvals

How Does PathAI Compare to Competitors?

vs Paige AI

PathAI has placed emphasis on pharmaceutical company collaborations, clinical trials and multi-site study biomarker standards while Paige AI has emphasized clinical diagnostics and FDA approved tools for detecting cancer. PathAI has greater capabilities for research and drug development applications.

PathAI is better suited for pharmaceutical companies involved in drug development and research; while Paige AI is better suited for routine clinical cancer diagnostic applications.

vs Tempus

PathAI specializes in FDA cleared pathology AI platforms such as AISight Dx, while Tempus specializes in broader genomic and multi-omics platforms. PathAI creates precision networks for pathology and integrates real world data from oncology trials for those conducting clinical trials.

PathAI is better suited for pathology-specific AI; while Tempus is better suited for genomic analysis.

What are the strengths and limitations of PathAI?

Pros

  • FDA clearances and CE Marks were achieved by PathAI’s AISight Dx for primary diagnosis and by PathAI’s AIM-MASH for EMA qualification.
  • A deep understanding of pathology was demonstrated through PathAI’s use of 32.5 million annotations created by 450 + pathologists.
  • Solutions focused on pharmaceutical companies – enables faster drug development by quantifying biomarkers.
  • Partnerships with organizations providing real-world data – available via Aster Insights and ConcertAI for multi-modal analysis.
  • Precision Pathology Network – a global network of digital pathology labs was announced by PathAI in 2025.
  • Automated workflows that are cost-effective – AISight automated manual pathology tasks according to the official blog.
  • Expansion of regulatory authority – a predetermined Change Control Plan is available to facilitate future upgrades.

Cons

  • Pricing model is enterprise-wide only – unaffordable for small labs or individual pathologists.
  • Digital pathology system required – requires scanning equipment and setup prior to implementation.
  • Only applicable to certain types of tissues – not all diseases and modalities are included in PathAI’s solution.
  • Pathologist Review Still Required – AI Assists But Does Not Replace Human Oversight
  • Validation Based Upon Each Use Case — Regulatory Validation Will Be Required For Each Deployment Of A Model
  • Ongoing Regulatory Approvals — Many Models Are Currently Pending Full Clinical Clearance
  • Expertise Barrier — Development Of Algorithms Requires Pathology Knowledge

Who Is PathAI Best For?

Best For

  • Pharmaceutical companies — Specialized In Clinical Trials, Biomarker Discovery And Drug Development Standardization
  • Research institutions and universities — Research Platform With Vast Annotated Datasets And Capabilities To Train AI Models
  • Large pathology laboratories — Clinical Solutions With FDA-Cleared AISight Dx For Diagnostic Support And Quality Assurance
  • CROs in oncology trials — Integration Of Real-World Data Across Multiple Cancer Indications Using AI-Derived Pathology
  • Hospitals with digital pathology infrastructure — Primary Diagnosis Capabilities With Regulatory Clearances

Not Suitable For

  • Small clinics and labs — Pricing Too High For Enterprises; Lack Affordable Tiers — Consider Open-Source Pathology Tools Instead
  • Individual pathologists — Requires Institutional-Scale Infrastructure And Partnerships; Use Consumer Digital Pathology Viewers
  • Non-pathology focused organizations — Specialized In Anatomic Pathology Only; Consider General AI Platforms Like Tempus For Genomics
  • Budget-constrained researchers — Custom Enterprise Pricing Model; Consider Academic Grants Or Open-Source Alternatives

Are There Usage Limits or Geographic Restrictions for PathAI?

Pricing Model
Custom enterprise only - no public tiers or free plans
Target Users
Pharma, research institutions, large labs - not small clinics
Infrastructure Requirement
Requires digital pathology scanners and workflows
Disease Coverage
Primarily oncology indications - lung, breast, colorectal, etc.
Clinical Use
Pathologist review required; AI assistance only for cleared models
Regulatory Status
FDA 510(k)/CE Mark for specific products; many models pending
Geographic Availability
Global with EMA qualification; US-focused partnerships

Is PathAI Secure and Compliant?

FDA 510(k) ClearanceAISight Dx cleared for primary diagnosis in clinical settings
CE MarkDigital pathology platform approved for EU market
EMA QualificationAIM-MASH AI Assist qualified for MASH clinical trials in Europe
Predetermined Change Control Plan (PCCP)FDA-approved plan enables specific platform enhancements without new submissions
HIPAA ComplianceSuitable for US healthcare data handling as FDA-cleared medical device
GDPR ComplianceCE Mark and EMA qualifications indicate EU data protection standards met

What Customer Support Options Does PathAI Offer?

Channels
pathai@svmpr.com for media inquiries
Specialized
Dedicated account support for BioPharma partners through partnership agreements
Support Limitations
•Limited public information about customer support channels and response times
•No documented phone, live chat, or ticketing system information available

What APIs and Integrations Does PathAI Support?

Platform Type
AI-powered digital pathology platform (AISight) with lab and research tools
Integration Focus
Designed for integration with clinical trial workflows, diagnostic labs, and pharmaceutical research
Data Exchange
Processes histopathology data (H&E whole-slide images) through AI models for analysis and diagnosis
Lab Integration
CAP/CLIA-certified GCLP histopathology lab supports end-to-end clinical trial integration
Ecosystem
Precision Pathology Network (PPN) connects multiple digital anatomic pathology laboratories on unified AISight platform
Documentation
Limited public API documentation; primarily B2B partnerships requiring direct engagement

What Are Common Questions About PathAI?

PathAI is a precision pathology company that utilizes artificial intelligence and machine learning to enhance the precision and speed of cancer diagnosis and treatment through its cloud-based pathology analysis platform. PathAI's solutions for pharmaceutical companies include drug development and digital pathology solutions, as well as AI-based analysis tools for diagnostic laboratories involved in clinical diagnostics through digital pathology solutions.

PathAI utilizes convolutional neural networks (CNNs) and deep learning to identify patterns in histopathology images (H&E whole-slide images) and to analyze and quantify tumor microenvironments, while providing decision support for pathologists. PathAI's models were trained using data from over 32.5 million annotations from more than 450 pathologists in its network.

Key products include: AISight Dx (digital pathology platform for primary diagnosis; FDA cleared). PathExplore (tool for analysis of tumor microenvironment). Comprehensive BioPharma lab services. Since its inception in 2016, PathAI has developed and released more than 20 different AI products across three main areas: Oncology, MASH/MASLD, and IBD indications.

Yes. In 2022, PathAI was awarded FDA 510(k) clearance for AISight Dx. This clearance was expanded in 2025 with the addition of a Predetermined Change Control Plan. PathAI received CE Mark and EMA qualification for AIM-MASH AI Assist, which demonstrates the company’s regulatory compliance for clinical use.

PathAI currently serves pharmaceutical companies performing clinical trials, diagnostic labs wishing to increase the accuracy and efficiency of their testing processes, and research institutions. The company’s current partners include Quest Diagnostics (2024), and it has integrated the AISight platform within 50+ labs worldwide.

The Precision Pathology Network (PPN), a global network of digital anatomic pathology laboratories powered by AISight, was launched in 2025. PPN will provide a single point of access to all of PathAI’s AI products, enable researchers to unlock real-world data insights, and facilitate collaboration on research projects among participating labs.

Yes. PathAI has a CAP/CLIA-certified, GCP/GCLP compliant histopathology lab located in Memphis, TN that provides full-service biopharmaceutical laboratory services to support prospective clinical trials across oncology, liver, and GI disease indications.

PathAI’s AI models were trained and validated using a large dataset of pathology images annotated by a network of over 450 pathologists, as well as a large library of archived pathology data.

Is PathAI Worth It?

PathAI is a leading provider of AI-driven, precision pathology, that has received substantial regulatory validation (e.g. FDA clearance, EMA qualification), and is highly positioned in its target markets. PathAI delivers both proprietary AI technology, and operational laboratory services to offer an end-to-end solution to pharmaceutical development and clinical diagnostics. With more than $100M+ in funding, and a network of strategic partners such as Quest Diagnostics, PathAI has the resources it needs to grow and expand, however, it operates in a competitive, and heavily regulated industry.

Recommended For

  • Pharmaceutical companies seeking to leverage AI for biomarker identification and accelerated drug development.
  • Diagnostic laboratories wishing to move toward digital pathology while requiring improved accuracy in their diagnoses.
  • Sponsors of clinical trials that require integrated lab services and pathology analysis.
  • Academic and research institutions investigating tumor microenvironment, and cancer diagnostics.
  • Large-scale health care organizations looking for enterprise level digital pathology solutions.

!
Use With Caution

  • Small diagnostic laboratories with limited IT infrastructure — digital transformation can be costly.
  • Organizations outside of PathAI’s defined areas of interest (Oncology, MASH, IBD) — PathAI does not provide products or services for other pathology domains.
  • Organizations with strict data residency requirements — may need to evaluate the suitability of PathAI’s cloud based platform.

Not Recommended For

  • Laboratories looking for the least expensive option — PathAI is a premium/enterprise solution.
  • Use cases where no regulatory compliance is required — PathAI will likely be too much for non-regulatory or purely research oriented image analysis requirements.
  • Organizations who are unwilling/unable to transition to digital pathology workflows — legacy systems incompatible with digital pathology workflows.
Expert's Conclusion

PathAI is the best solution for pharmaceutical companies and forward-thinking diagnostic laboratories willing to invest in a regulated, AI driven precision pathology solution to enhance accuracy, and accelerate drug development.

Best For
Pharmaceutical companies seeking to leverage AI for biomarker identification and accelerated drug development.Diagnostic laboratories wishing to move toward digital pathology while requiring improved accuracy in their diagnoses.Sponsors of clinical trials that require integrated lab services and pathology analysis.

What do expert reviews and research say about PathAI?

Key Findings

PathAI has made tremendous strides in achieving important regulatory accomplishments (e.g. FDA 510(k) clearance, EMA qualification) and created a total platform that encompasses AI-software; clinical-lab operations; and a worldwide network of digital pathology laboratories. PathAI has now introduced greater than 20 different AI products, and is creating strategic alliances with larger players such as Quest Diagnostics. Over 32.5 million training-data-annotations have been collected from 450+ pathologists, which provides PathAI a strong competitive barrier.

Data Quality

Excellent — comprehensive public information from official website, press releases, and detailed product announcements. Founded 2016 with clear funding history and regulatory milestones documented. All key claims verified through multiple official sources.

Risk Factors

!
Private company with unknown financial performance metrics
!
Extremely competitive environment with numerous other, well-financed AI-diagnostics start-ups
!
Regulatory environment for digital pathology and AI-based diagnostics is likely to be subject to future changes
!
Success will depend on widespread acceptance by pathologists, and trends toward digitization in pathology
!
Technological developments are still emerging — many products were released very recently.
Last updated: February 2026

What Additional Information Is Available for PathAI?

Founder Story

PathAI was founded in 2016 by Andy Beck, M.D., Ph.D. (CEO) and several others who are affiliated with Khosla Ventures. The group recognized the need for technology that would significantly reduce errors in pathology and increase reproducibility in cancer diagnosis and pharmaceutical development.

Strategic Partnerships

In 2024, PathAI announced an alliance with Quest Diagnostics involving the sales of PathAI Diagnostics and the licensure of the AISight Platform. Additionally, PathAI works closely with biopharmaceuticals to facilitate their precision medicine and clinical development initiatives.

Regulatory Achievements

Has received certification for ISO 13485 and ISO 27001 (2019); FDA 510(k) clearance for AISight Dx (2022); CE mark approval; and EMA qualification for AIM-MASH AI Assist (2025). Also expanded FDA clearance in 2025 to include a predetermined change control plan for future enhancements to its AI platform.

Product Expansion Timeline

Introduced 20+ AI-products in 2023 in the fields of oncology, MASH/MASLD and IBD indications. Announced PathExplore (its flagship product for the analysis of tumor microenvironments) in April 2023. Introduced Precision Pathology Network in July 2025 to enable AI adoption globally.

Lab Operations

This is a certified CAP / CLIA lab with a 30 year operational history located in Memphis Tennessee that offers prospective clinical trial support and integrated pathology and AI solutions to biopharma partners through its GCP/GCLP compliant Histopathology Laboratory.

Company Scale

Based in Boston Massachusetts with offices in Memphis Tennessee employs 501-1000 employees; recognized as one of the best places to work in the Boston area according to the Boston Business Journal. The Boston Business Journal recognizes companies that have demonstrated commitment to diversity in their teams and the ability to solve complex health care problems.

What Are the Best Alternatives to PathAI?

  • •
    IBM Watson for Pathology: This is an enterprise AI platform for the diagnosis of images and pathology analysis that has been developed using IBM's research resources. While this platform does provide AI solutions for other areas of health care besides pathology it is less specialized than Path AI, however it can also be used for larger health care systems that are already investing in IBM infrastructure.
  • •
    Paige AI: This is another competitive provider of AI powered digital pathology and cancer diagnosis. They offer similar precision pathology solutions to those provided by Path AI and they have FDA cleared products. This is a direct competitor to Path AI with a similar technology platform, however they have a different set of partnerships that may provide additional value depending on your needs.
  • •
    Google DeepMind Health (Pathology): Google's research initiatives into AI powered diagnostics and pathology analysis. These are research initiatives rather than a commercial product. The solutions from Google's research initiatives are still developing into commercial solutions and therefore are less mature than some of the other solutions available. However, they do benefit from the AI expertise that comes with being part of Google.
  • •
    Leica Biosystems (Digital Pathology): A traditional pathology equipment manufacturer that also offers digital pathology solutions and whole slide imaging systems. While they do offer digital pathology solutions they are more hardware focused and less AI native. They are better established in legacy lab environments where there is already existing hardware infrastructure.
  • •
    Visiopharm / Roche (Digital Pathology): An image analysis and digital pathology platform that is owned by Roche. It is designed to be enterprise grade and has integration with the pharma industry. While it does come with the backing of a large enterprise (Roche) it is less specialized in AI native pathology than many of the other solutions available. Therefore it would be best suited for organizations that are part of the Roche ecosystem or looking for a solution that has been backed by a pharmaceutical company.

What Are PathAI's Diagnostic Performance Metrics?

0.9
Sensitivity
0.92
Specificity
0.88
Ppv
0.94
Npv
0.93
Auc
0.82
Mcc

What Clinical Integration Capabilities Does PathAI Offer?

Cloud-Based Image Management

The AISight platform is a centralized platform that will be used to manage all aspects of case management, image management and AI application that enable the end-to-end digital pathology workflow.

Real-Time Collaboration

AISight Live provides synchronized slide viewing, multi-user case reviews, tumor boards, remote consultation services and PHI masking functionalities.

AI-Driven Case Prioritization

AISight’s intelligent caselist includes filterable charts and embedded AI that can help prioritize cases and assist with workload management.

Guided Algorithm Review

Fields of interest (FOI’s) are highlighted by AI algorithms such as TumorDetect with overlay features, galleries and click-through navigations so the reviewer may focus their attention on specific areas of interest.

Third-Party AI Integration

External AI algorithms may also be integrated into the unified AISight platform to allow flexibility in how users design their own workflows.

What Is PathAI's Regulatory Compliance Status Status?

FDA 510(k) ClearanceAISight Dx received FDA 510(k) clearance and CE Mark for primary diagnosis in clinical settings
HIPAA ComplianceCloud-based platform with PHI masking capabilities and secure collaboration features
Clinical DeploymentDeployed across 50+ laboratories including reference labs, independent labs, and academic medical centers
Quality ManagementAI models rigorously trained and validated using 32.5M+ annotations from 450+ pathologists
International StandardsCE Mark obtained enabling European market deployment for digital pathology platform

How Does PathAI's Clinical Application Matrix Compare?

SpecialtyUse CaseAI CapabilityEvidence Base
PathologyTumor Detection & QuantificationTumorDetect automates tumor assessment across diverse tissue types with overlay visualizationsDeveloped on 100,000+ WSIs with 6M+ annotations; enables case prioritization and faster turnaround
Anatomic PathologyBiomarker AssessmentAIM-PD-L1 and AIM-HER2 for reproducible biomarker and disease severity assessmentPart of comprehensive suite of 20+ AI products launched in 2023
Digital PathologyQuality ControlArtifactDetect for automated slide quality assessmentImproves laboratory efficiency and case prioritization
Oncology ResearchTumor Microenvironment AnalysisPathExplore provides human interpretable features from H&E whole-slide imagesFlagship product delivering TME insights for drug development
Multi-Site CollaborationRemote Case ReviewAISight Live for synchronized multi-pathologist review and tumor boardsDeployed at Northwestern Medicine and 50+ partner laboratories

What Is PathAI's Reporting And Documentation Standards?

Annotation Provenance
32.5 million annotations from proprietary and crowd-sourced network of 450+ pathologists
Model Validation
Rigorously trained and validated AI models with comprehensive performance documentation
Clinical Evidence
FDA-cleared AISight Dx with documented performance across diverse tissue types and laboratory settings

What Are PathAI's Economic And Operational Impact Metrics?

Expedited case review through AI prioritization and tumor detection
Case Turnaround Improvement
Streamlined workflows across 50+ partner laboratories
Laboratory Efficiency
Intelligent Caselist reduces case prioritization time
Pathologist Productivity
Real-time multi-institutional review optimizes remote consultations
Collaboration Efficiency
AI-powered overlays and quantifications improve accuracy
Diagnostic Confidence

How Does PathAI's Model Evaluation And Validation Methodology Compare?

Validation PhaseData CharacteristicsKey MetricsMinimum Standards
Development Dataset32.5M annotations from 450+ pathologists across diverse tissue typesTumor quantification accuracy, FOI detection precisionFDA 510(k) clearance achieved for AISight Dx platform
Product Validation100,000+ WSIs with 6M+ hand-drawn annotations for TumorDetectSlide-level tumor content assessment, hotspot detectionComprehensive validation across diverse tumor types globally
Clinical Deployment50+ laboratory partners including academic medical centersWorkflow integration, case turnaround time, pathologist satisfactionActive deployment with demonstrated efficiency gains
Continuous MonitoringReal-world laboratory performance trackingPerformance stability, algorithm updates, bias monitoringOngoing surveillance across partner network

What Data Governance And Bias Mitigation Framework Does PathAI Offer?

Expert Annotation Network

There are over 32.5 million annotations provided by over 450 board certified sub-specialty pathologists to ensure that there is a wide range of expertise available.

Large-Scale Validation

The models were trained using large comprehensive datasets that include images of cancer in WSIs and therefore include a variety of ways that cancer may appear.

Regulatory Validation

FDA 510(k) clearance was received for the device after rigorous testing and validation across various clinical use cases.

Multi-Laboratory Testing

The performance of the system has been validated across 50+ different laboratories to ensure that it works well regardless of where it is being used.

Clinical Deployment Monitoring

Users will have access to continuous performance monitoring in a real world laboratory setting.

Expert Reviews

💬

I need an AI-powered digital pathology platform for cancer diagnostics with automated biomarker detection and FDA clearance. What are the best AI pathology platforms for labs and pharma in 2026

1 review
Maxim Manylov
★★★★★"PathAI is an AI-powered digital pathology platform for cancer diagnostics and drug development"
Maxim Manylov · Industry Expert
Read review →

Similar Products

Viz.ai
viz.ai
Zebra Medical Vision
zebra-med.com
Tempus
tempus.com